<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03541525</url>
  </required_header>
  <id_info>
    <org_study_id>IMNIS2015-04</org_study_id>
    <nct_id>NCT03541525</nct_id>
  </id_info>
  <brief_title>Pathophysiological Explorations of Red Blood Cells</brief_title>
  <acronym>GR-Ex</acronym>
  <official_title>Pathophysiological Explorations of Red Blood Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imagine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imagine Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GR-Ex is a program labelled by Labex (Laboratory of Excellence) by the French Ministry of
      Higher Education and Research. This program aims to develop the means to improve knowledge in
      the physiology and pathologies of erythropoiesis, red blood cells and iron metabolism, and to
      develop new therapeutic protocols capable of providing added value in terms of innovation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">October 10, 2027</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Innovative markers of spleen fonctionality</measure>
    <time_frame>10 years</time_frame>
    <description>Retention rate (%) of red blood cells using Microsphiltration compared with non affected subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of inflammation in sickle cell disease</measure>
    <time_frame>10 years</time_frame>
    <description>Activation rate of circulating mastocytes (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of post-artesunate hemolysis</measure>
    <time_frame>10 years</time_frame>
    <description>Concentration of pitted red blood cells at day 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between transfusion yield and the storage of red blood cell bags</measure>
    <time_frame>10 years</time_frame>
    <description>Increasing in haemoglobin concentration at 6 hours post transfusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficiency of Phosphodiesterase inhibitor on neutrophil adhesion in Sickle cell disease</measure>
    <time_frame>10 years</time_frame>
    <description>Proportional change in adhesion rate (%) of neutrophils measured in the peripheral blood before and after treatment with phosphodiesterase inhibitors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of mitochondria removal during erythropoiesis in SDC patients, consequences on the mature RBC</measure>
    <time_frame>10 years</time_frame>
    <description>Mitochondria rate and level of ROS in RBC measured by Flow Cytometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study of iron metabolism in Diamond-Blackfan Anemia patients</measure>
    <time_frame>10 years</time_frame>
    <description>Dosage of iron metabolism parameters</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Red Blood Cell Disorder</condition>
  <arm_group>
    <arm_group_label>Affected patients</arm_group_label>
    <description>Biological samples of blood for all patients. Biological samples of saliva, surgical remainder (skin, tumor, kidney,....), saliva, urine, hair.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non affected relatives</arm_group_label>
    <description>Biological samples of blood for all relatives.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological sampling</intervention_name>
    <description>Biological samples including blood, surgical remainder, urine,...</description>
    <arm_group_label>Affected patients</arm_group_label>
    <arm_group_label>Non affected relatives</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Collection of:

        -  Blood samples

        -  Surgical remainders (tumor, skin, kidney,...)

        -  Urine

        -  Saliva

        -  Hair
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion of patients affected by red blood cell disorder and their non affected relatives
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be affected or have a family history of disease bound to the red blood cell,

          -  For adult subjects, have signed an informed consent form,

          -  For minor or major under legal safeguard subjects, the form must be signed by both
             parents (for minors) or by the legal representative,

          -  Be affiliated to health insurance.

        Exclusion Criteria:

          -  Being deprived of freedom
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Hermine, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joël Veiga</last_name>
    <phone>+33142754456</phone>
    <email>veigajoel@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre Buffet, MD</last_name>
    <phone>+33142754456</phone>
    <email>pabuffet@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Necker - Enfants malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermine Olivier</last_name>
      <phone>+ 33 1 44 49 54 16</phone>
      <email>oliver.hermine@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

